• london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Reading: Six-month dosing could simplify treatment to support millions of patients with severe asthma
Share
Notification
  • london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Have an existing account? Sign In
MedEdge MEA > Lead > Six-month dosing could simplify treatment to support millions of patients with severe asthma
LeadNews

Six-month dosing could simplify treatment to support millions of patients with severe asthma

ME Desk
ME Desk
Published: May 24, 2024
Share
3 Min Read
Six-Month Dosing Could Simplify Severe Asthma Treatment for Millions
SHARE

London, UK- 23 May 2024- GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count. Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualised rate of clinically significant exacerbations (asthma attacks) over 52 weeks. Patients treated with either depemokimab or placebo experienced similar overall incidence and severity of treatment-emergent adverse events across both trials. Further analysis of these data is ongoing.

Also read: GSK to become a founding partner of Fleming Initiative to fight AMR

Depemokimab is the first ultra-long-acting biologic to be evaluated in phase III trials with a binding affinity and high potency for interleukin-5 (IL-5), enabling six-month dosing intervals for patients with severe asthma. IL-5 is known to be a key cytokine (protein) in type 2 inflammation. This inflammation, typically identified by elevated blood eosinophil count, is the underlying pathology responsible for more than 80% of people with severe asthma and can lead to unpredictable exacerbations.

Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D, said: “These results add to the established body of evidence that targeted inhibition of IL-5 plays a key role in reducing type 2 inflammation that drives severe asthma exacerbations. Depemokimab could offer the possibility of sustained inhibition of this pathway, with a dosing schedule of just two injections per year. This is important as research shows that 73% of physicians believe longer dosing intervals would be beneficial to patients who are often juggling multiple therapies.”

Expertise in respiratory diseases and the science of IL-5 has informed the ongoing evidence generation program evaluating the impact of six-month dosing of sustained IL-5 inhibition in patients achieving clinical remission in severe asthma.5 The full results of SWIFT-1 and SWIFT-2 will be presented at an upcoming scientific congress and will be used to support regulatory submissions to health authorities worldwide.

Depemokimab is currently not approved anywhere in the world.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article Husband Donates Kidney in Inspiring ABO Incompatible Transplant Husband Donates Kidney in Inspiring ABO Incompatible Transplant
Next Article Atalanta Therapeutics Expands Executive Team with New Appointments Atalanta Therapeutics Expands Executive Team with New Appointments

Recent Posts

  • NMSS AND ERTH ZAYED PHILANTHROPIES SIGN AED 25 MILLION GRANT AGREEMENT TO MARK WORLD MS DAY
  • Liver Transplantation Enters the Era of Precision Diagnostics
  • Merck Gulf & Ovasave Host Women’s Health Forum in UAE
  • Inside Cleveland Clinic Abu Dhabi’s Heart Institute with Dr. Gopal Bhatnagar
  • Global Health Collaboration in Focus: Malek El Husseini at Abu Dhabi Global Health Week 2025
  • Dermatology expo rome
  • LifeSpin
  • Health ExpoIraq
  • Agora
Two Point Five Logo white
  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: Six-month dosing could simplify treatment to support millions of patients with severe asthma
Share

Published by Two Point Five Media FZCO

  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: Six-month dosing could simplify treatment to support millions of patients with severe asthma
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp
Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?